ANDA 78721, held by Sandoz. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 78721 (Ketorolac Tromethamine), held by Sandoz, was first approved by FDA on Nov 5, 2009, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2009 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine0.4% · solution/drops;ophthalmic | Ketorolac Tromethamine | Discontinued |
| May 15, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 18, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 5, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters